Und das bei der mir bekannten Story im Verhältnis zum Marktwert.
|
#260
As of April 3, 2020, we had issued and outstanding:
•6,132,393 shares of our common stock held by 194 stockholders of record; and
•options to purchase 666,444 shares of our common stock, at a weighted average exercise price of $24.64 per share.
•warrant to purchase 2,028,636 shares of our common stock, at a weighted average exercise of $16.61 per shares.
--------------------------------------------------
Warrants
2016, the Company issued 1,142,838 warrants / exercise price of $12.00 per share
(In March 2020, 254,769 of the November 2016 warrants were exercised for net proceeds of $3.1 million.)
2017, the Company issued warrants to purchase 1,296,650 shares / exercise price of $18.63 per share (As of December 31, 2019, all of these warrants were outstanding.)
As of April 3, 2020, we had issued and outstanding:
•6,132,393 shares of our common stock held by 194 stockholders of record; and
•options to purchase 666,444 shares of our common stock, at a weighted average exercise price of $24.64 per share.
•warrant to purchase 2,028,636 shares of our common stock, at a weighted average exercise of $16.61 per shares.
--------------------------------------------------
Warrants
2016, the Company issued 1,142,838 warrants / exercise price of $12.00 per share
(In March 2020, 254,769 of the November 2016 warrants were exercised for net proceeds of $3.1 million.)
2017, the Company issued warrants to purchase 1,296,650 shares / exercise price of $18.63 per share (As of December 31, 2019, all of these warrants were outstanding.)
Nach Angaben von BLPH sind im März 254769 der 1142838 Nov.16 Warrants zu 12$ ausgeübt worden. Vermutlich werden die Warranthalter bei diesen Kursen auch weiter machen.
Aber mal zum: "eine Information über den Einstig eines großen Pharmakonzern oder Übernahme "
Zum Pharmakonzern:
BLPH hält nur die Lizenz. Ohne die Erlaubniss von Ikaria läuft da gar nichts. Da Ikaria eine 100% Tochter von Mallinckrodt Pharmaceuticals ist, die selber ein Interesse an der Technologie haben, wird das wohl nichts.
Zur Übernahme
Wird BLPH übernommen geht die Technologie an Ikaria. Bringt also auch nichts. Wird Mallinckrodt Pharmaceuticals gleich mit übernommen, sind das ca. 320 Mio$ für beide Firmen, einschl. einem Sahnehäubchen von einem Mrd. Betrag an Schulden.
Glaube das kannst du dir abschminken! Auch wenn es so manch ein Börsenblatt in Aussicht stellt!
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 562 | BLPH | hulkier | MCTropper | 16.10.23 19:32 | |
11 | Rebound BLPH | Inlfu | AlternativplanB2017 | 05.06.23 15:13 | ||
3 | Skyrocker Bellerophon Therapeutics +181,34% | moneywork4me | moneywork4me | 25.04.21 02:25 | ||
2 | BLPH | hulkier | hulkier | 10.09.18 19:51 |